Vanguard Capital Management
AIDX

Vanguard Capital Management’s 20/20 Biolabs Inc AIDX Stock Holding History

Vanguard Capital Management’s Portfolio AIDX Stock Details AIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Buy
+24,530
New +$30.8K ﹤0.01% 4034

Other funds holding AIDX

CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.99B AUM 23.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $412M AUM 34.27% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

Vanguard Capital Management's AIDX Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in 20/20 Biolabs Inc (AIDX) in Q2 2026: 24,530 shares worth $13.5K. The stake represents ﹤0.01% of the portfolio and ranks #4034 among its holdings.

15 funds tracked by Wall St. Rank hold AIDX as of Q2 2026.

  • Vanguard Capital Management held 24,530 shares of 20/20 Biolabs Inc worth $13.5K as of Q2 2026.
  • 20/20 Biolabs Inc was a new Vanguard Capital Management position in Q2 2026.
  • 20/20 Biolabs Inc made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4034 holding.
  • 15 funds tracked by Wall St. Rank held 20/20 Biolabs Inc as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.